• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday

    6/21/24 10:45:13 AM ET
    $ADTN
    $ASAN
    $BA
    $CABA
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology
    Get the next $ADTN alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday.

    Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance.

    Asana said its board of directors approved a stock repurchase program authorizing the company to repurchase up to $150 million of its Class A common stock through June 30, 2025.

    Asana shares jumped 13.4% to $12.90 on Friday.

    Here are some other big stocks recording gains in today’s session.

    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares jumped 39.2% to $171.89 after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) shares gained 31% to $1.35 following insider buying from the company's co-founder. After the market close on Thursday, Clover Health filed a Form 4 with the SEC showing that co-founder and executive chair Vivek Garipalli purchased 877,567 shares of Clover Health stock at an average price of $1.14 per share.
    • Avid Bioservices, Inc. (NASDAQ:CDMO) climbed 13.7% to $7.75.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) rose 9.1% to $9.09.
    • ADTRAN Holdings, Inc. (NASDAQ:ADTN) climbed 8.7% to $5.65
    • Hertz Global Holdings, Inc. (NASDAQ:HTZ) gained 8.6% to $3.8150. The company revealed the upsize and pricing of $1 billion offerings, which comprised $750 million of First Lien Senior Secured Notes, which represents an upsize from the previously announced $500 million.
    • Studio City International Holdings Limited (NYSE:MSC) rose 8% to $6.75.
    • Codere Online Luxembourg, S.A. (NASDAQ:CDRO) gained 7.6% to $7.80.
    • Methode Electronics, Inc. (NYSE:MEI) jumped 7.1% to $10.74.
    • Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) gained 6.5% to $5.94. Ironwood Pharmaceuticals named Sravan K. Emany as Senior Vice President, Chief Operating Officer, and Chief Financial Officer.
    • Enviri Corporation (NYSE:NVRI) rose 6% to $8.86.
    • PTC Therapeutics, Inc. (NASDAQ:PTCT) gained 5.4% to $35.08. B of A Securities analyst Tazeen Ahmad maintained PTC Therapeutics with an Underperform and raised the price target from $25 to $32.
    • Spirit AeroSystems Holdings, Inc. (NYSE:SPR) rose 4.8% to $33.19. Boeing Co. (NYSE:BA) is reportedly close to finalizing a deal to reacquire Spirit AeroSystems, its former subsidiary, following significant progress in separate negotiations between Spirit and Airbus SE (OTC:EADSY) to divide Spirit's projects between the two aerospace giants.

    Now Read This: Wall Street’s Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

    Get the next $ADTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTN
    $ASAN
    $BA
    $CABA

    CompanyDatePrice TargetRatingAnalyst
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    ADTRAN Holdings Inc.
    $ADTN
    4/14/2026$18.00Outperform
    Evercore ISI
    PTC Therapeutics Inc.
    $PTCT
    4/10/2026$108.00Outperform
    Raymond James
    Boeing Company
    $BA
    4/1/2026$250.00Overweight
    Wells Fargo
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    Codere Online Luxembourg S.A.
    $CDRO
    1/30/2026$8.50Buy → Hold
    Stifel
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    More analyst ratings

    $ADTN
    $ASAN
    $BA
    $CABA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buckley Mortimer J bought $499,966 worth of shares (2,230 units at $224.20), increasing direct ownership by 101% to 4,430 units (SEC Form 4)

    4 - BOEING CO (0000012927) (Issuer)

    3/5/26 4:59:07 PM ET
    $BA
    Aerospace
    Industrials

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation. The inducement grant was approved by PTC's Compensation Committee o

    4/17/26 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi

    News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran's SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran's focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network' and ‘Artificial inte

    4/17/26 3:00:00 AM ET
    $ADTN
    Telecommunications Equipment
    Utilities

    ADTRAN Holdings, Inc. to release first quarter 2026 financial results on May 4, 2026

    ADTRAN Holdings, Inc. (NASDAQ:ADTN) ("ADTRAN Holdings" or the "Company") announced today that the Company will release its financial results for the first quarter 2026 after the market close on Monday, May 4, 2026, at https://investors.adtran.com/. The Company will conduct a conference call on Tuesday, May 5, 2026, to discuss the results for the quarter. What: ADTRAN Holdings, Inc. Earnings Call When: 7:30 a.m. Central Time (2:30 p.m. Central European Time) on Tuesday, May 5, 2026 The Company will webcast this conference call, or you may dial in to participate. To listen, visit the events and presentations section of ADTRAN Holdings, Inc. Investor Relations site at https://events.q4inc.

    4/16/26 4:05:00 PM ET
    $ADTN
    Telecommunications Equipment
    Utilities

    $ADTN
    $ASAN
    $BA
    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Evercore ISI initiated coverage on ADTRAN with a new price target

    Evercore ISI initiated coverage of ADTRAN with a rating of Outperform and set a new price target of $18.00

    4/14/26 8:04:53 AM ET
    $ADTN
    Telecommunications Equipment
    Utilities

    Raymond James initiated coverage on PTC Therapeutics with a new price target

    Raymond James initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $108.00

    4/10/26 8:34:55 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Priest Brady Patrick

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/16/26 8:37:09 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 4 filed by Soares Karen

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/16/26 8:25:08 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 4 filed by Toy Andrew

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/16/26 4:13:28 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    SEC Filings

    View All

    Boeing Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BOEING CO (0000012927) (Filer)

    4/17/26 2:54:44 PM ET
    $BA
    Aerospace
    Industrials

    SEC Form PRE 14A filed by Cabaletta Bio Inc.

    PRE 14A - Cabaletta Bio, Inc. (0001759138) (Filer)

    4/17/26 7:45:22 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Hertz Global Holdings Inc

    DEFA14A - HERTZ GLOBAL HOLDINGS, INC (0001657853) (Filer)

    4/16/26 4:07:49 PM ET
    $HTZ
    Rental/Leasing Companies
    Consumer Discretionary

    $ADTN
    $ASAN
    $BA
    $CABA
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

    WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise.  "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors," said Michael Schmertzler, Chairman of the Board of Directors. "Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth."Ms. Ch

    3/25/26 8:30:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana to Appoint Aziz Megji to the Role of Chief Financial Officer

    Asana, Inc. (NYSE:ASAN)(LTSE: ASAN), the system of action where humans and AI run work together, will promote Aziz Megji to the role of Chief Financial Officer (CFO), effective March 24, 2026. Megji will succeed Sonalee Parekh, who has served as Asana's CFO since 2024 and tendered her resignation effective March 23, 2026. Megji brings his experience from his Head of Financial Planning & Analysis role where he led the company's annual planning, budgeting, forecasting, and performance management processes, as well as overseeing the strategic finance, treasury, investor relations, corporate development, deal desk, and sales compensation functions. He partners closely with Asana's CEO and Boa

    3/2/26 4:06:00 PM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ADTN
    $ASAN
    $BA
    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ADTN
    $ASAN
    $BA
    $CABA
    Financials

    Live finance-specific insights

    View All

    ADTRAN Holdings, Inc. to release first quarter 2026 financial results on May 4, 2026

    ADTRAN Holdings, Inc. (NASDAQ:ADTN) ("ADTRAN Holdings" or the "Company") announced today that the Company will release its financial results for the first quarter 2026 after the market close on Monday, May 4, 2026, at https://investors.adtran.com/. The Company will conduct a conference call on Tuesday, May 5, 2026, to discuss the results for the quarter. What: ADTRAN Holdings, Inc. Earnings Call When: 7:30 a.m. Central Time (2:30 p.m. Central European Time) on Tuesday, May 5, 2026 The Company will webcast this conference call, or you may dial in to participate. To listen, visit the events and presentations section of ADTRAN Holdings, Inc. Investor Relations site at https://events.q4inc.

    4/16/26 4:05:00 PM ET
    $ADTN
    Telecommunications Equipment
    Utilities

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Hertz Global Holdings, Inc. to Announce First Quarter 2026 Financial Results on May 7, 2026

    Hertz Global Holdings, Inc. (NASDAQ:HTZ) (the "Company") announced today that it plans to report its first quarter 2026 financial results at 8:00 a.m. ET on Thursday, May 7, 2026, followed by an earnings call at 9:00 a.m. ET. A live webcast of the call will be available on the Investor Relations page of the Company's website at https://ir.hertz.com. To access the call by phone, please register through this link: Hertz Q1 2026 earnings teleco registration, and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A web replay will remain available on the website for approxima

    4/6/26 4:30:00 PM ET
    $HTZ
    Rental/Leasing Companies
    Consumer Discretionary